Clinical Trial Update: Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, anti-tumor activity, and pharmacology of IPH2101 in combination with lenalidomide in patients with multiple myeloma experie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• IPH2101
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Innate Pharma | Conditions: Patients With Multiple Myeloma Experiencing a, First or Second Relapse | Phase 1 | Status: COMPLETED